Long-term outcomes of a course of deep TMS for treatment-resistant OCD
- PMID: 34982981
- DOI: 10.1016/j.brs.2021.12.011
Long-term outcomes of a course of deep TMS for treatment-resistant OCD
Conflict of interest statement
Declaration of competing interest Tal Harmelech is a BrainsWay employee. Aron Tendler is the Chief Medical Officer of BrainsWay and has a financial interest in BrainsWay as well as a commercial clinical and research TMS center. He has received speaking fees from BrainsWay, Neuronetics and the Clinical TMS Society. Yiftach Roth is a key inventor of the Deep TMS technology, Chief Scientist at BrainsWay and has a financial interest in BrainsWay.